SLV-2436 | CAT#2095704-43-9 | MNK1/MNK2 inhibitor

MedKoo Cat#: 462548 | Name: SLV-2436

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SLV-2436 is a highly potent and ATP-competitive inhibitor of MNK1 and MNK2.

Chemical Structure

SLV-2436

CAS#2095704-43-9

Theoretical Analysis

MedKoo Cat#: 462548

Name: SLV-2436

CAS#: 2095704-43-9

Chemical Formula: C19H15ClN4O

Exact Mass: 350.0934

Molecular Weight: 350.81

Elemental Analysis: C, 65.05; H, 4.31; Cl, 10.11; N, 15.97; O, 4.56

Price and Availability

Size	Price	Availability
25mg	USD 250.00	2 Weeks
50mg	USD 450.00	2 Weeks
100mg	USD 750.00	2 Weeks
200mg	USD 1,350.00	2 Weeks
500mg	USD 2,350.00	2 Weeks
1g	USD 3,250.00	2 Weeks
2g	USD 5,450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

SLV-2436; SLV 2436; SLV2436; SEL201-88; SEL 201-88; SEL-201-88; SEL201; SEL 201; SEL-201;

IUPAC/Chemical Name

5-(3-amino-1H-indazol-6-yl)-1-(3-chlorobenzyl)pyridin-2(1H)-one

InChi Key

YQVUADHJKWJHAF-UHFFFAOYSA-N

InChi Code

InChI=1S/C19H15ClN4O/c20-15-3-1-2-12(8-15)10-24-11-14(5-7-18(24)25)13-4-6-16-17(9-13)22-23-19(16)21/h1-9,11H,10H2,(H3,21,22,23)

SMILES Code

ClC1=CC(CN2C(C=CC(C3=CC(NN=C4N)=C4C=C3)=C2)=O)=CC=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

SLV-2436 is a highly potent and ATP-competitive inhibitor of MNK1 and MNK2 with IC50s of 10.8 nM and 5.4 nM, respectively.

In vitro activity:

Findings from this study indicate that blocking MNK1/2 exerts potent antimelanoma effects, which could be potential strategy to treat patients positive for KIT mutations. SLV-2436-treated KIT-mutant melanoma cells had lower oncogenicity and reduced metastatic ability. Reference: J Clin Invest. 2017 Nov 1;127(11):4179-4192. https://pubmed.ncbi.nlm.nih.gov/29035277/

In vivo activity:

SLV-2436 blocked ductal carcinoma in situ progression to invasive disease in vivo. Reference: Cancer Res. 2019 Apr 1;79(7):1646-1657. https://pubmed.ncbi.nlm.nih.gov/30659022/

Preparing Stock Solutions

The following data is based on the product molecular weight 350.81 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Kosciuczuk EM, Kar AK, Blyth GT, Fischietti M, Abedin S, Mina AA, Siliezar R, Rzymski T, Brzozka K, Eklund EA, Beauchamp EM, Eckerdt F, Saleiro D, Platanias LC. Inhibitory effects of SEL201 in acute myeloid leukemia. Oncotarget. 2019 Dec 24;10(67):7112-7121. doi: 10.18632/oncotarget.27388. PMID: 31903169; PMCID: PMC6935253. 2. Zhan Y, Guo J, Yang W, Goncalves C, Rzymski T, Dreas A, Żyłkiewicz E, Mikulski M, Brzózka K, Golas A, Kong Y, Ma M, Huang F, Huor B, Guo Q, da Silva SD, Torres J, Cai Y, Topisirovic I, Su J, Bijian K, Alaoui-Jamali MA, Huang S, Journe F, Ghanem GE, Miller WH Jr, Del Rincón SV. MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma. J Clin Invest. 2017 Nov 1;127(11):4179-4192. doi: 10.1172/JCI91258. Epub 2017 Oct 16. PMID: 29035277; PMCID: PMC5663367. 3. Guo Q, Li VZ, Nichol JN, Huang F, Yang W, Preston SEJ, Talat Z, Lefrère H, Yu H, Zhang G, Basik M, Gonçalves C, Zhan Y, Plourde D, Su J, Torres J, Marques M, Habyan SA, Bijian K, Amant F, Witcher M, Behbod F, McCaffrey L, Alaoui-Jamali M, Giannakopoulos NV, Brackstone M, Postovit LM, Del Rincón SV, Miller WH Jr. MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma In Situ. Cancer Res. 2019 Apr 1;79(7):1646-1657. doi: 10.1158/0008-5472.CAN-18-1602. Epub 2019 Jan 18. PMID: 30659022; PMCID: PMC6513674.

In vitro protocol:

In vivo protocol:

1. Guo Q, Li VZ, Nichol JN, Huang F, Yang W, Preston SEJ, Talat Z, Lefrère H, Yu H, Zhang G, Basik M, Gonçalves C, Zhan Y, Plourde D, Su J, Torres J, Marques M, Habyan SA, Bijian K, Amant F, Witcher M, Behbod F, McCaffrey L, Alaoui-Jamali M, Giannakopoulos NV, Brackstone M, Postovit LM, Del Rincón SV, Miller WH Jr. MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma In Situ. Cancer Res. 2019 Apr 1;79(7):1646-1657. doi: 10.1158/0008-5472.CAN-18-1602. Epub 2019 Jan 18. PMID: 30659022; PMCID: PMC6513674.

1: Zhan Y, Guo J, Yang W, et al. MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma. J Clin Invest. 2017;127(11):4179-4192. doi:10.1172/JCI91258

View History

Aricine hydrobromide

MedKoo CAT#: 575005

CAS#: 5978-89-2